on ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics to Present Data on Lusvertikimab at DDW 2025
OSE Immunotherapeutics will present new findings from the Phase 2 extension of their CoTikiS trial at the Digestive Disease Week conference in San Diego, focusing on Lusvertikimab for ulcerative colitis. The Open Label Extension (OLE) study spans 24 weeks and evaluates the long-term benefits and safety of this anti-IL-7 receptor monoclonal antibody.
Previously, the induction period results were highlighted at the 2025 ECCO congress. The new data promises deeper insights into Lusvertikimab's potential, not only for ulcerative colitis but also other autoimmune diseases.
The conference session, "Lusvertikimab, a First in Class IL7 Receptor Antagonist, in Moderate to Severe Ulcerative Colitis," will take place on May 5, 2025. Lusvertikimab continues to be a promising candidate amidst high remission challenges in ulcerative colitis.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ORPHAN SYNERGY EUROPE-PHARMA news